Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin Prolonged-Release vs Glucophage XR in Healthy Fed Subjects
NCT05124717Phase 1Completed
- Sponsor
- Farmak
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Farmak. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration and Maximum plasma concentration. Started Jun 2019; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05124717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124717.